SARS-CoV-2 nucleocapsid protein with Enhanced T-cell Stimulation Domain (N-ETSD)

SARS-CoV-2 nucleocapsid protein with Enhanced T-cell Stimulation Domain (N-ETSD) is an engineered vaccine antigen designed to elicit a robust and broad cellular immune response against COVID-19. While most first-generation vaccines target the highly mutable spike protein, the nucleocapsid (N) protein is significantly more conserved across viral variants, offering the potential for more durable protection (ImmunityBio, 2021). The N-ETSD construct incorporates a specific signal sequence that directs the translated N protein to the endosomal and lysosomal compartments within host cells (Frontiers in Immunology, 2021). This intracellular targeting facilitates the loading of N-protein peptides onto MHC class II molecules, which are then presented to CD4+ T helper cells. This mechanism significantly enhances the magnitude of the T-cell response and promotes a Th1-biased profile, which is critical for effective viral clearance and long-term immunological memory (MDPI, 2020). N-ETSD is a core component of next-generation multivalent vaccine candidates, such as ImmunityBio's hAd5-S-N, which aim to provide universal protection against emerging SARS-CoV-2 variants (News-Medical, 2021).

Other names

N-ETSDNucleocapsid-ETSDSARS-CoV-2 N protein with ETSDhAd5-S-N antigen

The Enhanced T-cell Stimulation Domain (ETSD) is a signal sequence fused to the nucleocapsid protein that directs it to the endosomal/lysosomal compartment of antigen-presenting cells. This targeting enhances the processing and presentation of viral epitopes via the MHC class II pathway, leading to increased CD4+ T-cell activation and a Th1-biased immune response (Frontiers in Immunology, 2021; ImmunityBio, 2021).